These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 19934815

  • 1. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy.
    Lima LH, Zweifel SA, Engelbert M, Sorenson JA, Slakter JS, Cooney MJ, Klancnik JM, Yannuzzi LA, Freund KB.
    Retina; 2009 Oct; 29(9):1213-7. PubMed ID: 19934815
    [Abstract] [Full Text] [Related]

  • 2. We congratulate the authors for publishing their data on bilateral consecutive intravitreal injections administered in their office.
    Shah GY, Ambatipudi S, Fernandes M, Lakshmipathy M, Varma PV, Sachdeva V, Pathengay A.
    Retina; 2010 Sep; 30(8):1325-6; author reply 1326-7. PubMed ID: 20827150
    [No Abstract] [Full Text] [Related]

  • 3. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.
    Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS, Hollands H, Sharma S.
    Retina; 2008 Sep; 28(10):1395-9. PubMed ID: 18827737
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection.
    Mason JO, White MF, Feist RM, Thomley ML, Albert MA, Persaud TO, Yunker JJ, Vail RS.
    Retina; 2008 Apr; 28(4):564-7. PubMed ID: 18398358
    [Abstract] [Full Text] [Related]

  • 6. Bilateral intravitreal injection of antivascular endothelial growth factor therapy.
    Mahajan VB, Elkins KA, Russell SR, Boldt HC, Gehrs KM, Weingeist TA, Stone EM, Abràmoff MD, Liu D, Folk JC.
    Retina; 2011 Jan; 31(1):31-5. PubMed ID: 21187731
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
    Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J, Klancnik J, Cooney M.
    Am J Ophthalmol; 2008 May; 145(5):879-82. PubMed ID: 18329624
    [Abstract] [Full Text] [Related]

  • 9. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
    Shah CP, Garg SJ, Vander JF, Brown GC, Kaiser RS, Haller JA, Post-Injection Endophthalmitis (PIE) Study Team.
    Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
    [Abstract] [Full Text] [Related]

  • 10. Histopathology of streptococcus mitis/oralis endophthalmitis after intravitreal injection with bevacizumab: a report of 7 patients.
    Matthews JL, Dubovy SR, Goldberg RA, Flynn HW.
    Ophthalmology; 2014 Mar; 121(3):702-8. PubMed ID: 24439760
    [Abstract] [Full Text] [Related]

  • 11. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor.
    Mezad-Koursh D, Goldstein M, Heilwail G, Zayit-Soudry S, Loewenstein A, Barak A.
    Retina; 2010 Mar; 30(7):1051-7. PubMed ID: 20616683
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections.
    Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam WC.
    Ophthalmology; 2012 Aug; 119(8):1609-14. PubMed ID: 22480743
    [Abstract] [Full Text] [Related]

  • 15. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection.
    Chong DY, Anand R, Williams PD, Qureshi JA, Callanan DG.
    Retina; 2010 Oct; 30(9):1432-40. PubMed ID: 20559156
    [Abstract] [Full Text] [Related]

  • 16. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
    Ronan SM, Yoganathan P, Chien FY, Corcóstegui IA, Blumenkranz MS, Deramo VA, Elner SG, Fastenberg DA, Johnson MW, López M, Mateo C, Moshfeghi DM, Navarro R, Rosenblatt BJ, Sanislo SR, Saxe SJ, Zacks DN.
    Retina; 2007 Jun; 27(5):535-40. PubMed ID: 17558313
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
    Inoue M, Kobayakawa S, Sotozono C, Komori H, Tanaka K, Suda Y, Matsushima H, Kinoshita S, Senoo T, Tochikubo T, Kadonosono K.
    Ophthalmologica; 2011 Jun; 226(3):145-50. PubMed ID: 21811052
    [Abstract] [Full Text] [Related]

  • 18. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch.
    Yamashiro K, Tsujikawa A, Miyamoto K, Oh H, Otani A, Tamuara H, Ooto S, Sasahara M, Iwama D, Yoshimura N.
    Retina; 2010 Mar; 30(3):485-90. PubMed ID: 19952993
    [Abstract] [Full Text] [Related]

  • 19. Pars plana vitrectomy in the management of patients diagnosed with endophthalmitis following intravitreal anti-vascular endothelial growth factor injection.
    Chaudhary KM, Romero JM, Ezon I, Fastenberg DM, Deramo VA.
    Retina; 2013 Mar; 33(7):1407-16. PubMed ID: 23492945
    [Abstract] [Full Text] [Related]

  • 20. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration.
    Wickremasinghe SS, Michalova K, Gilhotra J, Guymer RH, Harper CA, Wong TY, Qureshi S.
    Ophthalmology; 2008 Nov; 115(11):1911-5. PubMed ID: 18672291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.